Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Fujirebio

News headline image
Fujirebio Expands Access in Canada to Blood-based Neurology Testing with Health Canada Class II Medical Device Licenses for the Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma Assays
From Fujirebio
Via Business Wire
News headline image
Fujirebio Announces CE Marking of the Fully Automated Lumipulse® G pTau 217 Plasma Assay
From Fujirebio
Via Business Wire
News headline image
Fujirebio and Sysmex Begin Sales Collaboration for Dementia Testing
From Fujirebio
Via Business Wire
News headline image
Fujirebio Expands Its Neuro Testing Portfolio With the Launch of the Fully Automated Lumipulse® G pTau 217 CSF Assay for Research Use Only
From Fujirebio
Via Business Wire
News headline image
Notice Concerning Change of Representative Executive Officer
From Fujirebio
Via Business Wire
News headline image
Fujirebio Acquires Plasma Services Group and Strengthens Its Position as Provider of Critical and High Quality Biological Raw Materials to the IVD and Life Science Industries
From Fujirebio
Via Business Wire
News headline image
Fujirebio Announces Strategic Collaboration with Stanford Medicine to Advance Infectious Disease Research
From Fujirebio
Via Business Wire
News headline image
Fujirebio Expands Its Neuro Testing Portfolio With the Launch of the Fully Automated Lumipulse® G sTREM2 Assay for Research Use Only
From Fujirebio
Via Business Wire
News headline image
Fujirebio Receives Marketing Clearance for Lumipulse® G pTau 217/ β-Amyloid 1-42 Plasma Ratio In-vitro Diagnostic Test as an Aid to Identify Patients With Amyloid Pathology Associated With Alzheimer’s Disease
From FUJIREBIO
Via Business Wire
News headline image
Grant Award from GHIT Fund for Development of an Ultrasensitive Urine Test for Tuberculosis
From Fujirebio
Via Business Wire
News headline image
Fujirebio and Eisai Enter into Memorandum of Understanding for Joint Research and Social Implementation of Blood-based Biomarkers in the Field of Neurodegenerative Diseases
From Fujirebio
Via Business Wire
News headline image
ADx NeuroSciences and Alamar Biosciences Announce Partnership to Provide Customized Blood-Based Biomarker Assay Solutions to Accelerate Biopharma Clinical Development
From Fujirebio
Via Business Wire
News headline image
Fujirebio Submits FDA Regulatory Filing for Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio In-Vitro Diagnostic Test as an Aid to Identify Patients With Amyloid Pathology Associated With Alzheimer’s Disease
From Fujirebio
Via Business Wire
News headline image
Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Pathology in Alzheimer’s Disease
From Fujirebio
Via Business Wire
News headline image
Fujirebio Launches the Fully Automated Lumipulse® G GFAP Assay for Research Use Only and Further Strengthens its Neuro Test Menu
From Fujirebio
Via Business Wire
News headline image
Beckman Coulter and Fujirebio Expand Partnership to Develop Patient-friendly, Blood-based Neurodegenerative Disease Diagnostics
From FUJIREBIO
Via Business Wire
News headline image
Fujirebio and Agappe Enter into an Agreement on Business Collaboration in the Field of CLIA Based Immunoassay
From FUJIREBIO
Via Business Wire
News headline image
Fujirebio Expands Its Alzheimer’s Disease Test Menu With the Much Awaited and Fully Automated Lumipulse® G pTau 217 Plasma Assay for Research Use Only (RUO)
From Fujirebio
Via Business Wire
News headline image
Fujirebio and Sysmex Sign Agreement for the Supply of Reagent Raw Materials in the Field of Immunoassay
From FUJIREBIO
Via Business Wire
News headline image
Fujirebio expands its assay menu in the field of neurodegenerative diseases with the launch of the fully automated Lumipulse® G NfL CSF and Lumipulse® G NfL Blood tests
From Fujirebio
Via Business Wire
News headline image
Fujirebio Europe Receives Translational Research Funding From Alzheimer’s Drug Discovery Foundation for Development of a Fully Automated Plasma pTau181 Testing Solution
From Fujirebio
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.